Jazz Pharmaceuticals JAZZ Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax by Product | ||||||
| Defitelio/defibrotide | $206.13M+3.4% | $199.43M+0.6% | $198.21M-6.6% | $212.27M+1.3% | $209.59M-3.2% | |
| Epidiolex/Epidyolex | $1.09B+3.0% | $1.06B+1.2% | $1.05B+5.1% | $996.04M+0.5% | $991.41M+2.0% | |
| High-sodium oxybate AG royalty revenue | $199.08M-6.0% | $211.68M+0.2% | $211.29M-2.4% | $216.5M0.0% | $216.53M-0.5% | |
| Modeyso | $89.44M+86.2% | $48.04M+318% | $11.5M+2,347% | $470K— | —— | |
| Other | $12.56M-37.7% | $20.16M+1.7% | $19.83M-0.4% | $19.91M+9.4% | $18.2M+58.7% | |
| Rylaze/Enrylaze | $412.39M+2.4% | $402.89M+1.7% | $396.21M+0.3% | $395.13M-1.8% | $402.3M-2.1% | |
| Vyxeos | $143.77M-2.0% | $146.67M-11.2% | $165.18M+2.0% | $161.91M+1.1% | $160.07M-1.6% | |
| Xyrem | $139.99M-4.1% | $145.99M-7.3% | $157.5M-12.5% | $179.95M-13.0% | $206.78M-11.6% | |
| Xywav | $1.72B+3.8% | $1.66B+4.0% | $1.59B+2.8% | $1.55B+3.1% | $1.5B+2.0% | |
| Zepzelca | $345.28M+12.4% | $307.28M+4.1% | $295.16M-2.2% | $301.71M-2.1% | $308.22M-3.8% | |
| Ziihera | $36.14M+45.5% | $24.84M+43.2% | $17.35M+91.9% | $9.04M+196% | $3.05M+190% | |
| Revenue from Contract with Customer, Excluding Assessed Tax by Geography | ||||||
| All other | $95.28M+0.4% | $94.88M0.0% | $94.86M-4.8% | $99.61M+10.7% | $90.02M-6.4% | |
| Europe | $350.48M+2.6% | $341.68M+2.1% | $334.65M+2.8% | $325.57M+0.2% | $324.96M+3.9% | |
| U.S. | $3.99B+4.2% | $3.83B+2.8% | $3.73B+1.8% | $3.66B+0.3% | $3.65B-0.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Jazz Pharmaceuticals break its business down?
- Jazz Pharmaceuticals (JAZZ) reports revenue from contract with customer, excluding assessed tax by product across 12 parts — Defitelio/defibrotide, Epidiolex/Epidyolex, High-sodium oxybate AG royalty revenue, Modeyso and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Jazz Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Jazz Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
